Catestatin (Chromogranin A352-372) and novel effects on mobilization of fat from adipose tissue through regulation of adrenergic and leptin signaling

Journal of Biological Chemistry

Volumn 287, Issue 27, 2012, Pages 23141-23151

  Bandyopadhyay, Gautam K ^a,b   Vu, Christine U ^b   Gentile, Stefano ^b   Lee, Howon ^b   Biswas, Nilima ^b   Chi, Nai Wen ^a,b   O'Connor, Daniel T ^a,b   Mahata, Sushil K ^a,b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTES; ADIPOSE TISSUE; ADRENERGIC RECEPTORS; FATTY ACID OXIDATION; KNOCK OUTS; LEPTIN RECEPTORS; LEPTIN SIGNALING; LIPOLYTIC; METABOLIC PHENOTYPE; OBESE MICE; PHENYLEPHRINE; PHOSPHOLIPASE C ACTIVATIONS; REDUCED FAT; UP-REGULATION;

ENZYME INHIBITION; GENES; HORMONES; LIPIDS; NUTRITION; OXIDATION; PHENOLS; PHOSPHORYLATION; SIGNALING; TISSUE;

MAMMALS;

ALPHA ADRENERGIC RECEPTOR; CARNITINE PALMITOYLTRANSFERASE I; CATESTATIN; CD36 ANTIGEN; CYCLIC AMP; ISOPRENALINE; LEPTIN; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHENTOLAMINE; PHENYLEPHRINE; PHOSPHOLIPASE C; STAT3 PROTEIN; UNCOUPLING PROTEIN 2;

ACOX GENE; ADIPOCYTE; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; CD36 GENE; CONTROLLED STUDY; CPT1ALPHA GENE; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FATTY ACID OXIDATION; GENE; GPAT GENE; HORMONE SENSITIVITY; HYPERLEPTINEMIA; LIPID STORAGE; LIPOLYSIS; MALE; MOUSE; NONHUMAN; OBESITY; PPARALPHA GENE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UCP2 GENE; UPREGULATION;

ADIPOCYTES; ADIPOSE TISSUE; ANIMALS; ANTI-OBESITY AGENTS; CATECHOLAMINES; CHROMOGRANIN A; FATTY ACIDS; GENE EXPRESSION; LEPTIN; LIPOLYSIS; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, OBESE; OBESITY; PEPTIDE FRAGMENTS; PRIMARY CELL CULTURE; RECEPTORS, ADRENERGIC, ALPHA; SIGNAL TRANSDUCTION;

MUS;

EID: 84863327807     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M111.335877     Document Type: Article

References (64)

1. Winkler, H., and Fischer-Colbrie, R. (1992) The chromogranins A and B. The first 25 years and future perspectives. Neuroscience 49, 497-528
2. Taupenot, L., Harper, K. L., and O'Connor, D. T. (2003) The chromogranin-secretogranin family. New Engl. J. Med. 348, 1134-1149 (Pubitemid 36337325)
3. Montero-Hadjadje, M., Vaingankar, S., Elias, S., Tostivint, H., Mahata, S. K., and Anouar, Y. (2008) Chromogranins A and B and secretogranin II. Evolutionary and functional aspects. Acta Physiol. (Oxf.) 192, 309-324 (Pubitemid 351187645)
4. Tatemoto, K., Efendić, S., Mutt, V., Makk, G., Feistner, G. J., and Barchas, J. D. (1986) Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature 324, 476-478 (Pubitemid 17184167)
5. Sánchez-Margalet, V., González-Yanes, C., Najib, S., and Santos-Alvarez, J. (2010) Metabolic effects and mechanism of action of the chromogranin A-derived peptide pancreastatin. Regul. Pept. 161, 8-14
6. Aardal, S., Helle, K. B., Elsayed, S., Reed, R. K., and Serck-Hanssen, G. (1993) Vasostatins, comprising the N-terminal domain of chromogranin A, suppress tension in isolated human blood vessel segments. J. Neuroendocrinol. 5, 405-412 (Pubitemid 23243499)
7. Mahata, S. K., O'Connor, D. T., Mahata, M., Yoo, S. H., Taupenot, L., Wu, H., Gill, B. M., and Parmer, R. J. (1997) Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J. Clin. Invest. 100, 1623-1633 (Pubitemid 27425790)
8. Mahapatra, N. R., O'Connor, D. T., Vaingankar, S. M., Hikim, A. P., Mahata, M., Ray, S., Staite, E., Wu, H., Gu, Y., Dalton, N., Kennedy, B. P., Ziegler, M. G., Ross, J., and Mahata, S. K. (2005) Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J. Clin. Invest. 115, 1942-1952 (Pubitemid 40979734)
9. Mahata, S. K., Mahata, M., Fung, M. M., and O'Connor, D. T. (2010) Catestatin. A multifunctional peptide from chromogranin A. Regul. Pept. 162, 33-43
10. Theurl, M., Schgoer, W., Albrecht, K., Jeschke, J., Egger, M., Beer, A. G., Vasiljevic, D., Rong, S., Wolf, A. M., Bahlmann, F. H., Patsch, J. R., Wolf, D., Schratzberger, P., Mahata, S. K., and Kirchmair, R. (2010) The neuropeptide catestatin acts as a novel angiogenic cytokine via a basic fibroblast growth factor-dependent mechanism. Circ. Res. 107, 1326-1335
11. Fung, M. M., Salem, R. M., Mehtani, P., Thomas, B., Lu, C. F., Perez, B., Rao, F., Stridsberg, M., Ziegler, M. G., Mahata, S. K., and O'Connor, D. T. (2010) Direct vasoactive effects of the chromogranin A (CHGA) peptide catestatin in humans in vivo. Clin. Exp. Hypertens. 32, 278-287
12. Gaede, A. H., and Pilowsky, P. M. (2012) Catestatin, a chromogranin A-derived peptide, is sympathoinhibitory and attenuates sympathetic baro-sensitivity and the chemoreflex in rat CVLM. Am. J. Physiol. Regul. Integr. Comp. Physiol. 302, R365-R372
13. Angelone, T., Quintieri, A. M., Brar, B. K., Limchaiyawat, P. T., Tota, B., Mahata, S. K., and Cerra, M. C. (2008) The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism. Endocrinology 149, 4780-4793
14. Mazza, R., Gattuso, A., Mannarino, C., Brar, B. K., Barbieri, S. F., Tota, B., and Mahata, S. K. (2008) Catestatin (chromogranin A344-364) is a novel cardiosuppressive agent. Inhibition of isoproterenol and endothelin signaling in the frog heart. Am. J. Physiol. Heart Circ. Physiol. 295, H113-H122
15. Imbrogno, S., Garofalo, F., Cerra, M. C., Mahata, S. K., and Tota, B. (2010) The catecholamine release-inhibitory peptide catestatin (chromogranin A344-363) modulates myocardial function in fish. J. Exp. Biol. 213, 3636-3643
16. Gayen, J. R., Gu, Y., O'Connor, D. T., and Mahata, S. K. (2009) Global disturbances in autonomic function yield cardiovascular instability and hypertension in the chromogranin a null mouse. Endocrinology 150, 5027-5035
17. Gaede, A. H., and Pilowsky, P. M. (2010) Catestatin in rat RVLM is sympathoexcitatory, increases barosensitivity, and attenuates chemosensitivity and the somatosympathetic reflex. Am. J. Physiol. Regul. Integr. Comp. Physiol. 299, R1538-R1545
18. Dev, N. B., Gayen, J. R., O'Connor, D. T., and Mahata, S. K. (2010) Chromogranin a and the autonomic system. Decomposition of heart rate variability and rescue by its catestatin fragment. Endocrinology 151, 2760-2768
19. Briolat, J., Wu, S. D., Mahata, S. K., Gonthier, B., Bagnard, D., Chasserot-Golaz, S., Helle, K. B., Aunis, D., and Metz-Boutigue, M. H. (2005) New antimicrobial activity for the catecholamine release-inhibitory peptide from chromogranin A. Cell Mol. Life Sci. 62, 377-385 (Pubitemid 40379251)
20. Radek, K. A., Lopez-Garcia, B., Hupe, M., Niesman, I. R., Elias, P. M., Taupenot, L., Mahata, S. K., O'Connor, D. T., and Gallo, R. L. (2008) The neuroendocrine peptide catestatin is a cutaneous antimicrobial and induced in the skin after injury. J. Invest. Dermatol. 128, 1525-1534 (Pubitemid 351693209)
21. Aung, G., Niyonsaba, F., Ushio, H., Kajiwara, N., Saito, H., Ikeda, S., Ogawa, H., and Okumura, K. (2011) Catestatin, a neuroendocrine antimicrobial peptide, induces human mast cell migration, degranulation and production of cytokines and chemokines. Immunology 132, 527-539
22. 2+-calcineurin-NFAT signaling pathway. Biochem. Biophys. Res. Commun. 407, 807-812
23. Egger, M., Beer, A. G., Theurl, M., Schgoer, W., Hotter, B., Tatarczyk, T., Vasiljevic, D., Frauscher, S., Marksteiner, J., Patsch, J. R., Schratzberger, P., Djanani, A. M., Mahata, S. K., and Kirchmair, R. (2008) Monocyte migration. Anovel effect and signaling pathways of catestatin. Eur. J. Pharmacol. 598, 104-111
24. Sugawara, M., Resende, J. M., Moraes, C. M., Marquette, A., Chich, J. F., Metz-Boutigue, M. H., and Bechinger, B. (2010) Membrane structure and interactions of human catestatin by multidimensional solution and solid-state NMR spectroscopy. FASEB J. 24, 1737-1746
25. Helle, K. B. (2010) The chromogranin A-derived peptides vasostatin-I and catestatin as regulatory peptides for cardiovascular functions. Cardiovasc. Res. 85, 9-16
26. Arner, P. (1999) Catecholamine-induced lipolysis in obesity. Int. J. Obes. Relat. Metab. Disord. 23, (Suppl. 1) 10-13
27. Arner, P. (2005) Human fat cell lipolysis. Biochemistry, regulation and clinical role. Best Pract. Res. Clin. Endocrinol. Metab. 19, 471-482
28. Lafontan, M., Barbe, P., Galitzky, J., Tavernier, G., Langin, D., Carpene, C., Bousquet-Melou, A., and Berlan, M. (1997) Adrenergic regulation of adipocyte metabolism. Hum. Reprod. 12, (Suppl. 1) 6-20
29. 2-adrenergic receptors by epinephrine during exercise in human adipose tissue. Am. J. Physiol. 277, R1076-1083
30. 2-adrenergic receptors blunts epinephrine-induced lipolysis in subcutaneous adipose tissue during a hyperinsulinemic euglycemic clamp in men. Am. J. Physiol. Endocrinol. Metab. 285, E599-E607
31. Lafontan, M., and Langin, D. (2009) Lipolysis and lipid mobilization in human adipose tissue. Prog. Lipid Res. 48, 275-297
32. Mori, S., Nojiri, H., Yoshizuka, N., and Takema, Y. (2007) Rapid desensitization of lipolysis in the visceral and subcutaneous adipocytes of rats. Lipids 42, 307-314 (Pubitemid 46668926)
33. Jensen, M. D. (1997) Lipolysis. Contribution from regional fat. Annu. Rev. Nutr. 17, 127-139
34. Bougnères, P., Stunff, C. L., Pecqueur, C., Pinglier, E., Adnot, P., and Ricquier, D. (1997) In vivo resistance of lipolysis to epinephrine. A new feature of childhood onset obesity. J. Clin. Invest. 99, 2568-2573 (Pubitemid 27259802)
35. Lafontan, M., and Berlan, M. (1993) Fat cell adrenergic receptors and the control of white and brown fat cell function. J. Lipid Res. 34, 1057-1091 (Pubitemid 23199155)
36. Townsend, R. R., Klein, S., and Wolfe, R. R. (1994) Changes in lipolytic sensitivity following repeated epinephrine infusion in humans. Am. J. Physiol. 266, E155-E160
37. Stallknecht, B., Bülow, J., Frandsen, E., and Galbo, H. (1997) Desensitization of human adipose tissue to adrenaline stimulation studied by microdialysis. J. Physiol. 500, 271-282 (Pubitemid 27165850)
38. Gayen, J. R., Saberi, M., Schenk, S., Biswas, N., Vaingankar, S. M., Cheung, W. W., Najjar, S. M., O'Connor, D. T., Bandyopadhyay, G., and Mahata, S. K. (2009) A novel pathway of insulin sensitivity in chromogranin A null mice. A crucial role for pancreastatin in glucose homeostasis. J. Biol. Chem. 284, 28498-28509
39. Fritsche, A., Wahl, H. G., Metzinger, E., Renn, W., Kellerer, M., Häring, H., and Stumvoll, M. (1998) Evidence for inhibition of leptin secretion by catecholamines in man. Exp. Clin. Endocrinol. Diabetes 106, 415-418 (Pubitemid 28491208)
40. 2-adrenergic receptors. Eur. J. Endocrinol. 143, 439-445
41. Couillard, C., Mauriège, P., Prud'homme, D., Nadeau, A., Tremblay, A., Bouchard, C., and Després, J. P. (2002) Plasma leptin response to an epinephrine infusion in lean and obese women. Obes. Res. 10, 6-13 (Pubitemid 135686625)
42. Thalmann, S., Juge-Aubry, C. E., and Meier, C. A. (2008) Explant cultures of white adipose tissue. Methods Mol. Biol. 456, 195-199
43. Karnieli, E., Zarnowski, M. J., Hissin, P. J., Simpson, I. A., Salans, L. B., and Cushman, S. W. (1981) Insulin-stimulated translocation of glucose transport systems in the isolated rat adipose cell. Time course, reversal, insulin concentration dependency, and relationship to glucose transport activity. J. Biol. Chem. 256, 4772-4777 (Pubitemid 11035332)
44. Bandyopadhyay, G. K., Yu, J. G., Ofrecio, J., and Olefsky, J. M. (2005) Increased p85/55/50 expression and decreased phosphotidylinositol 3-kinase activity in insulin-resistant human skeletal muscle. Diabetes 54, 2351-2359 (Pubitemid 41134262)
45. Bandyopadhyay, G. K., Yu, J. G., Ofrecio, J., and Olefsky, J. M. (2006) Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects. Diabetes 55, 2277-2285 (Pubitemid 44743625)
46. Mao, X., Kikani, C. K., Riojas, R. A., Langlais, P., Wang, L., Ramos, F. J., Fang, Q., Christ-Roberts, C. Y., Hong, J. Y., Kim, R. Y., Liu, F., and Dong, L. Q. (2006) APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat. Cell Biol. 8, 516-523
47. Seeley, R. J., van Dijk, G., Campfield, L. A., Smith, F. J., Burn, P., Nelligan, J. A., Bell, S. M., Baskin, D. G., Woods, S. C., and Schwartz, M. W. (1996) Intraventricular leptin reduces food intake and body weight of lean rats but not obese Zucker rats. Horm. Metab. Res. 28, 664-668 (Pubitemid 27057912)
48. Minokoshi, Y., Kim, Y. B., Peroni, O. D., Fryer, L. G., Müller, C., Carling, D., and Kahn, B. B. (2002) Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415, 339-343 (Pubitemid 34087557)
49. Wang, M. Y., Orci, L., Ravazzola, M., and Unger, R. H. (2005) Fat storage in adipocytes requires inactivation of leptin's paracrine activity. Implications for treatment of human obesity. Proc. Natl. Acad. Sci. U.S.A. 102, 18011-18016 (Pubitemid 41798493)
50. Knight, Z. A., Hannan, K. S., Greenberg, M. L., and Friedman, J. M. (2010) Hyperleptinemia is required for the development of leptin resistance. PLoS One 5, e11376
51. Kim, Y. B., Uotani, S., Pierroz, D. D., Flier, J. S., and Kahn, B. B. (2000) In vivo administration of leptin activates signal transduction directly in insulin-sensitive tissues. Overlapping but distinct pathways from insulin. Endocrinology 141, 2328-2339 (Pubitemid 32269051)
52. Morris, D. L., and Rui, L. (2009) Recent advances in understanding leptin signaling and leptin resistance. Am. J. Physiol. Endocrinol. Metab. 297, E1247-E1259
53. Vaisse, C., Halaas, J. L., Horvath, C. M., Darnell, J. E., Jr., Stoffel, M., and Friedman, J. M. (1996) Leptin activation of Stat3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice. Nat. Genet. 14, 95-97 (Pubitemid 26301554)
54. El-Haschimi, K., Pierroz, D. D., Hileman, S. M., Bjørbaek, C., and Flier, J. S. (2000) Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. J. Clin. Invest. 105, 1827-1832 (Pubitemid 30421764)
55. Lin, S., Thomas, T. C., Storlien, L. H., and Huang, X. F. (2000) Development of high fat diet-induced obesity and leptin resistance in C57Bl/6J mice. Int. J. Obes. Relat. Metab. Disord. 24, 639-646 (Pubitemid 30323498)
56. Van Heek, M., Compton, D. S., France, C. F., Tedesco, R. P., Fawzi, A. B., Graziano, M. P., Sybertz, E. J., Strader, C. D., and Davis, H. R., Jr. (1997) Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J. Clin. Invest. 99, 385-390 (Pubitemid 27414794)
57. Pelleymounter, M. A., Cullen, M. J., Baker, M. B., Hecht, R., Winters, D., Boone, T., and Collins, F. (1995) Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269, 540-543
58. Koch, C., Augustine, R. A., Steger, J., Ganjam, G. K., Benzler, J., Pracht, C., Lowe, C., Schwartz, M. W., Shepherd, P. R., Anderson, G. M., Grattan, D. R., and Tups, A. (2010) Leptin rapidly improves glucose homeostasis in obese mice by increasing hypothalamic insulin sensitivity. J. Neurosci. 30, 16180-16187
59. Frühbeck, G., Aguado, M., and Martínez, J. A. (1997) In vitro lipolytic effect of leptin on mouse adipocytes. Evidence for a possible autocrine/paracrine role of leptin. Biochem. Biophys. Res. Commun. 240, 590-594
60. Frühbeck, G., Aguado, M., Gómez-Ambrosi, J., and Martínez, J. A. (1998) Lipolytic effect of in vivo leptin administration on adipocytes of lean and ob/ob mice, but not db/db mice. Biochem. Biophys. Res. Commun. 250, 99-102
61. Mahata, S. K., Mahata, M., Wakade, A. R., and O'Connor, D. T. (2000) Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A344-364). Identification of amino acid residues crucial for activity. Mol. Endocrinol. 14, 1525-1535
62. Mahata, S. K., Mahata, M., Wen, G., Wong, W. B., Mahapatra, N. R., Hamilton, B. A., and O'Connor, D. T. (2004) The catecholamine release-inhibitory "catestatin" fragment of chromogranin A. Naturally occurring human variants with different potencies for multiple chromaffin cell nicotinic cholinergic responses. Mol. Pharmacol. 66, 1180-1191 (Pubitemid 39411058)
63. 3-adrenergic agonist in rats. Int. J. Mol. Med. 8, 103-109
64. 2-adrenergic receptor-mediated antilipolysis in human adipose tissue. J. Lipid Res. 48, 2236-2246